Stephanie Shaw, MD
Endocrinology, Diabetes & Metabolism · Round Rock, TXNPI 1760687354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 40.3% of the total. 2025 is the largest year on record at $691, more than ten times the $45 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TX, where the typical reported total is $2,974.
Across 111 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$633
- Lilly USA, LLC$126
- Abbott$107
- Insulet Corporation$76
- Intuitive Surgical$70
- BETA Bionics, Inc.$68
- plus $492 from 15 others
Across 673 payments — averaging $1388.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$934K
What the payments were for
- Food & beverage$1,53998%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $633 |
| Lilly USA, LLC | 7 | $126 |
| Abbott | 7 | $107 |
| Insulet Corporation | 4 | $76 |
| Intuitive Surgical | 1 | $70 |
| BETA Bionics, Inc. | 3 | $68 |
| Ascendis Pharma Endocrinology Inc | 2 | $54 |
| Cequr Corporation | 1 | $53 |
| Amgen | 3 | $51 |
| Medtronic(2 entities) | 2 | $42 |
| Corcept Therapeutics | 2 | $39 |
| IBSA Pharma Inc. | 2 | $36 |
| Tandem Diabetes Care, Inc. | 3 | $32 |
| Ascensia Diabetes Care US Inc. | 1 | $31 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Acella Pharmaceuticals, LLC | 1 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
How this compares
$1,572 in reported general payments places this provider in the 35th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 156 | $207,389 |
| Teriparatide | 53 | $167,444 |
| OzempicSemaglutide | 83 | $89,757 |
| JardianceEmpagliflozin | 55 | $55,561 |
| SynthroidLevothyroxine Sodium | 209 | $20,651 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $20,100 |
| Norditropin FlexproSomatropin | 13 | $18,674 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $18,395 |
| Repatha SureclickEvolocumab | 15 | $17,190 |
| LyumjevInsulin Lispro-Aabc | 13 | $16,713 |
| TirosintLevothyroxine Sodium | 23 | $8,168 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $7,974 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,019 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $4,125 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 44 | $2,819 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Lyumjev | $126 | $224,102169 claims |
| Novo NordiskOzempic | $633 | $89,75783 claims |
| IBSA Pharma Inc.Tirosint | $36 | $8,16823 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $25 | $2,517140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Round Rock
- Kerem OzerRound Rock$220K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.